WESTFORD, Mass., Nov. 1, 2016 /PRNewswire/ -- Cynosure, Inc.
(NASDAQ: CYNO), a leading developer and manufacturer of aesthetic
treatment systems, today announced the promotion of Douglas J. Delaney, Executive Vice President of
Worldwide Sales, to Chief Commercial Officer (CCO). In his new
role, Mr. Delaney will lead all sales and revenue initiatives
across the Company, including identifying new revenue sources and
driving new opportunities for growth. He reports to Michael Davin, President and Chief Executive
Officer.
"Doug's leadership and experience in creating a world-class
global sales organization at Cynosure, combined with the results he
has achieved over his 13-year tenure, make him uniquely qualified
to move into this new position," Mr. Davin said. "The performance
of our direct sales force in North
America, Asia and
Europe is directly attributable to
Doug's skill in business development, planning and execution, as
well as his ability to build strong relationships with our
customers and partners. As CCO, Doug's focus will expand to
ensuring that all activities within the Company are aligned to meet
our strategic commercial objectives. He has done an outstanding job
in leading our sales team, and he will play a central role as we
continue to deliver the highest quality products and services to
our customers."
A seasoned executive with more than 25 years of experience in
the aesthetic laser and medical equipment markets, Mr. Delaney
joined Cynosure in 2003 as Director of North American Sales.
He became Vice President of North American Sales in 2004 and
was promoted to Executive Vice President of Sales in 2005. In
June 2013, Mr. Delaney was promoted
to Executive Vice President of Worldwide Sales. Before joining
Cynosure, he was national sales manager at Cutera, Inc.
About Cynosure, Inc.
Cynosure develops, manufactures,
and markets aesthetic treatment systems that enable plastic
surgeons, dermatologists and other medical practitioners to perform
non-invasive and minimally invasive procedures to remove hair,
treat vascular and benign pigmented lesions, remove multi-colored
tattoos, revitalize the skin, reduce fat through non-invasive and
minimally invasive laser lipolysis, reduce cellulite, clear nails
infected by toe fungus, ablate sweat glands and improve
gynecological health. Cynosure also markets radiofrequency
energy-sourced medical devices for precision surgical applications
such as facial plastic and general surgery, gynecology, ear, nose,
and throat procedures, ophthalmology, oral and maxillofacial
surgery, podiatry and proctology. Cynosure's product portfolio is
composed of a broad range of energy sources including Alexandrite,
diode, Nd: YAG, picosecond, pulse dye, Q-switched lasers, intense
pulsed light and radiofrequency technology. Cynosure sells its
products globally under the Cynosure, Palomar, ConBio and Ellman
brand names through a direct sales force in the United States, Canada, France, Morocco, Germany, Spain, the United
Kingdom, Australia,
China, Japan and Korea, and through international
distributors in approximately 120 other countries. For
corporate or product information, visit Cynosure's website at
www.cynosure.com.
Forward-Looking Statements
This press release
contains forward-looking statements, within the meaning of the
federal securities laws, about our business prospects and
management transition. Any statements contained herein that are not
statements of historical fact may be deemed to be forward-looking
statements. Without limiting the foregoing, the words "believes,"
"plans," "intends," "expects," "goals" and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these words. Our future results
may differ materially from our past results and from those
projected in the forward-looking statements due to various
uncertainties and risks, including, but not limited to, those
described in Item 1A of Part II (Risk Factors) of our Quarterly
Report on Form 10-Q for the three months ended June 30, 2016.
The forward-looking statements speak only as of the date of this
press release and undue reliance should not be placed on these
statements. We disclaim any obligation to update any
forward-looking statements contained herein after the date of this
press release.
Contact:
Scott Solomon
Senior Vice President
Sharon Merrill Associates, Inc.
617.542.5300
cyno@investorrelations.com
Photo - http://photos.prnewswire.com/prnh/20161031/434401
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cynosure-promotes-doug-delaney-to-chief-commercial-officer-300354831.html
SOURCE Cynosure, Inc.